154 related articles for article (PubMed ID: 16149602)
21. Efficient screening for ovarian cancers using a combination of tumor markers CA602 and CA546.
Saito M; Aoki D; Susumu N; Suzuki A; Suzuki N; Udagawa Y; Nozawa S
Int J Gynecol Cancer; 2005; 15(1):37-44. PubMed ID: 15670295
[TBL] [Abstract][Full Text] [Related]
22. [CA72-4 (TAG-72)].
Maida Y; Kyo S; Inoue M
Nihon Rinsho; 2005 Aug; 63 Suppl 8():672-4. PubMed ID: 16149608
[No Abstract] [Full Text] [Related]
23. [CEA in nipple discharge].
Yagihashi A
Nihon Rinsho; 2005 Aug; 63 Suppl 8():635-6. PubMed ID: 16149598
[No Abstract] [Full Text] [Related]
24. Combination of markers may prove useful in screening for ovarian CA.
Oncology (Williston Park); 1994 Jun; 8(6):79-80. PubMed ID: 8074986
[No Abstract] [Full Text] [Related]
25. [Does follow-up of false-negative CA-125 serum values in tumor after-care of ovarian cancer make sense?].
Sevelda P; Rosen A; Barrada M; Gober S; Vavra N; Salzer H
Gynakol Rundsch; 1990; 30 Suppl 1():210-1. PubMed ID: 2079273
[No Abstract] [Full Text] [Related]
26. [CA130].
Hogaki M
Nihon Rinsho; 1999 Dec; 57 Suppl():466-9. PubMed ID: 10778166
[No Abstract] [Full Text] [Related]
27. [Tumor marker CA 72-4 in ovarian cancer in comparison with CA 125 and D-dimer].
Schelling M; Jänicke F; Senekowitsch R; Lörken A
Gynakol Rundsch; 1991; 31 Suppl 2():286-9. PubMed ID: 1665138
[No Abstract] [Full Text] [Related]
28. [DU-PAN-2, SPan-1].
Motoo Y; Sawabu N
Nihon Rinsho; 2005 Aug; 63 Suppl 8():687-90. PubMed ID: 16149612
[No Abstract] [Full Text] [Related]
29. [Sialyl Tn antigen].
Kannagi R
Nihon Rinsho; 1999 Dec; 57 Suppl():482-7. PubMed ID: 10778170
[No Abstract] [Full Text] [Related]
30. [High CA-125 values in a patient with miliary tuberculosis and ascites].
Klein M; Marczewski A; Rosen A; Beck A
Gynakol Rundsch; 1989; 29 Suppl 2():355-6. PubMed ID: 2613049
[No Abstract] [Full Text] [Related]
31. [STN (sialyl Tn antigen)].
Kannagi R
Nihon Rinsho; 2010 Jul; 68 Suppl 7():698-702. PubMed ID: 20960853
[No Abstract] [Full Text] [Related]
32. Unique case of massive ascites, extreme elevation of serum CA 125 tumour marker.
Jotkowitz MW; Gee DC
Aust N Z J Obstet Gynaecol; 1993 Nov; 33(4):453-4. PubMed ID: 8179576
[No Abstract] [Full Text] [Related]
33. [A study of preclinical and clinical usefulness of new tumor markers of ovarian carcinoma, CA 54/61 and CA 602. 1. Evaluation of the diagnostic accuracy of CA 54/61, a study of the normal range of its values and its correlation with other tumor markers].
Nozawa S; Udagawa Y; Sasaki H; Ito K; Akiya K; Terashima Y; Takamizawa H; Ohkura H; Fujimoto S; Hasimoto M
Gan To Kagaku Ryoho; 1992 Jun; 19(6):827-35. PubMed ID: 1605661
[TBL] [Abstract][Full Text] [Related]
34. [Clinical applications of ovarian cancer biomarkers].
Kataoka F; Aoki D
Nihon Rinsho; 2012 Jun; 70 Suppl 4():543-8. PubMed ID: 23156306
[No Abstract] [Full Text] [Related]
35. Tumor markers in ovarian carcinoma.
Dudzinski MR
Curr Opin Obstet Gynecol; 1990 Feb; 2(1):52-6. PubMed ID: 2102306
[No Abstract] [Full Text] [Related]
36. [Lysophospholipids].
Nakamura K; Yatomi Y
Nihon Rinsho; 2005 Aug; 63 Suppl 8():809-11. PubMed ID: 16149647
[No Abstract] [Full Text] [Related]
37. [Basic fibroblast growth factor (bFGF/FGF-2) in urine].
Ishiwata T; Naito Z
Nihon Rinsho; 2005 Aug; 63 Suppl 8():768-70. PubMed ID: 16149636
[No Abstract] [Full Text] [Related]
38. [Tumor markers of ovarian cancer].
Nozawa S
Rinsho Byori; 1992 Apr; 40(4):349-53. PubMed ID: 1593759
[TBL] [Abstract][Full Text] [Related]
39. Tumor markers in epithelial ovarian cancer. Clinical applications.
Hempling RE
Obstet Gynecol Clin North Am; 1994 Mar; 21(1):41-61. PubMed ID: 8015766
[TBL] [Abstract][Full Text] [Related]
40. [A clinical evaluation of the CA 72-4 serum level as a possible tumor marker].
Jibiki K; Takeda M; Abe H; Ito M; Odagiri E; Demura R; Demura H; Takizawa K
Gan No Rinsho; 1990 Oct; 36(12):2146-52. PubMed ID: 2232183
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
